Here is the design of a clinical trial:

Official Title: Does a Clinic Based Complex Care Coordination Intervention Improve Patient Quality Outcomes in an Underserved Clinic Population? the Streamlined, Unified, Meaningfully Managed Interdisciplinary Team (SUMMIT) Ambulatory ICU Study

Included conditions:
- Health Services
- Comorbidity
- Primary Health Care

Study Armgroups:
- {'label': 'SUMMIT intervention group', 'type': 'EXPERIMENTAL', 'description': 'This group will transfer primary care to the SUMMIT team, which consists of: 1 primary care provider, 1 clinical nurse, 1 team manager, 2 care-coordinators, 2 behavioralists, 1 clinical pharmacist. This interdisciplinary team will have reduced patient panel load and increased flexibility in time and scheduling in order to foster trust and continuity with the patient with a goal of decreasing treatment burden and increasing patient capacity. Specific activities that participants will receive include: 1) comprehensive initial intake and care plan development that incorporates patient goal setting; 2) flexible scheduling of appointments with outreach; 3) transitional care coordination; 4) built-in behavioural counselling and case management; 5) regular review of care plan by team members.', 'interventionNames': ['Other: SUMMIT intervention']}
- {'label': 'enhanced usual care group', 'type': 'ACTIVE_COMPARATOR', 'description': "This group will continue to receive primary care as usual for 6 months. This includes care provided by the patient's existing primary care provider, access to a clinic's Health Resilience outreach worker, mental health consultation, and other services provided by usual care. After 6 months, the baseline survey is administered and the participant will transfer care to the intervention as described above in the SUMMIT intervention group.", 'interventionNames': ['Other: Enhanced usual care']}

Interventions:
- {'type': 'OTHER', 'name': 'SUMMIT intervention', 'description': 'See description in experimental arm.', 'armGroupLabels': ['SUMMIT intervention group'], 'otherNames': ['intensive primary care team, complex care team']}
- {'type': 'OTHER', 'name': 'Enhanced usual care', 'description': 'See description in active comparator arm.', 'armGroupLabels': ['enhanced usual care group'], 'otherNames': ['usual care']}

Primary Outcomes:
- {'measure': 'Medical Hospitalizations', 'description': 'Administrative data will be used to determine hospital admissions', 'timeFrame': '6 months'}
- {'measure': 'Emergency Care visits', 'description': 'Administrative data will be used to determine Emergency Department (ED) visits over study period', 'timeFrame': '6 months'}
- {'measure': 'Primary care utilization', 'description': 'Clinic administrative data will be used to determine primary care visits over study period', 'timeFrame': '6 months'}
- {'measure': 'Patient Activation Measure (PAM)', 'description': 'Study survey of the PAM measure is a validated instrument to assess patient self-efficacy', 'timeFrame': '6 months'}
- {'measure': 'Patient Experience (ambulatory CAHPS)', 'description': 'Study survey of patient reported assessment of patient experience', 'timeFrame': '6 months'}

Please estimate the sample size based on the assumption: 
80% power, 2-tailed alpha, standard deviation of 1.9 for hospitalizations and 10 for PAM score
Sample size calculations
        We conducted several sample size calculations to estimate the study size population.
        We examined the sample size necessary to demonstrate a 40% reduction in our primary outcomes of hospital utilization over 6Â months. We determined average number of hospitalizations over the prior 6Â months for a pilot sample of SUMMIT patients (2.3 hospitalizations/person over 6Â months, SDâ=â1.9). Assuming 80% power and 2-tailed alpha, the sample size estimated was 140 participants. Based on preliminary data, we believed 400 existing patients met SUMMIT eligibility for utilization, but targeted an enrollment of 200 based on potential difficulties with recruitment and retention. We used prior literature to determine an effect size of a four-point increase on the secondary outcome of PAM score, with standard deviation of 10; therefore, at 80% power and 2 tailed alpha, the sample size estimated was 196 [41].